Found: 5
Select item for more details and to access through your institution.
Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 1, p. 29, doi. 10.1007/s40261-021-01100-y
- By:
- Publication type:
- Article
Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 5, p. 385, doi. 10.1016/j.clml.2023.02.006
- By:
- Publication type:
- Article
Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma.
- Published in:
- EJHaem, 2022, v. 3, n. 1, p. 97, doi. 10.1002/jha2.312
- By:
- Publication type:
- Article
Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 6, p. 886, doi. 10.1002/cncr.35107
- By:
- Publication type:
- Article
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 3, p. 492, doi. 10.1111/bjh.15806
- By:
- Publication type:
- Article